Skip to main content
main-content
Erschienen in: Strahlentherapie und Onkologie 4/2022

01.03.2022 | Rhabdomyosarkome | Literatur kommentiert

Genomische Klassifizierung und Überleben von Patienten mit Rhabdomyosarkom: Bericht eines internationalen Konsortiums

verfasst von: PD Dr. med. Monika Sparber-Sauer

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Auszug

Das Rhabdomyosarkom (RMS) ist das häufigste Weichteilsarkom im Kindesalter [ 1]. Trotz aggressiver Therapie ist die 5‑Jahres-Überlebensrate für Patienten mit metastasierter oder rezidivierender Erkrankung nach wie vor schlecht, und neben dem PAX-FOXO1-Fusionsstatus gibt es bisher keine genomischen Marker für die Risikoabschätzung. Shern et al. stellen nun eine internationale Studie zur Bestimmung der Häufigkeit von Treibermutationen („driver mutations“) und deren Zusammenhang mit dem Überleben vor. …
Zugang erhalten Sie mit:
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
1.
Zurück zum Zitat Skapek SX et al (2019) Rhabdomyosarcoma. Nat Rev Dis Primers 5(1):1 CrossRef Skapek SX et al (2019) Rhabdomyosarcoma. Nat Rev Dis Primers 5(1):1 CrossRef
2.
Zurück zum Zitat Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the children’s oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 59(1):5–10 CrossRef Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the children’s oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 59(1):5–10 CrossRef
3.
Zurück zum Zitat Oberlin O et al (2008) Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26(14):2384–2389 CrossRef Oberlin O et al (2008) Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26(14):2384–2389 CrossRef
4.
Zurück zum Zitat Klingebiel T et al (2008) Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 50(4):739–745 CrossRef Klingebiel T et al (2008) Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 50(4):739–745 CrossRef
5.
Zurück zum Zitat Meza JL et al (2006) Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol 24(24):3844–3851 CrossRef Meza JL et al (2006) Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol 24(24):3844–3851 CrossRef
6.
Zurück zum Zitat Newton WA Jr. et al (1995) Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification—an Intergroup Rhabdomyosarcoma Study. Cancer 76(6):1073–1085 CrossRef Newton WA Jr. et al (1995) Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification—an Intergroup Rhabdomyosarcoma Study. Cancer 76(6):1073–1085 CrossRef
7.
Zurück zum Zitat Barr FG (1997) Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 19(6):483–491 CrossRef Barr FG (1997) Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 19(6):483–491 CrossRef
8.
Zurück zum Zitat Pappo AS, Shapiro DN, Crist WM (1997) Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am 44(4):953–972 CrossRef Pappo AS, Shapiro DN, Crist WM (1997) Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am 44(4):953–972 CrossRef
9.
Zurück zum Zitat Hibbitts E et al (2019) Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the children’s oncology group. Cancer Med 8(14):6437–6448 CrossRef Hibbitts E et al (2019) Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the children’s oncology group. Cancer Med 8(14):6437–6448 CrossRef
10.
Zurück zum Zitat Missiaglia E et al (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30(14):1670–1677 CrossRef Missiaglia E et al (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30(14):1670–1677 CrossRef
12.
Zurück zum Zitat Skapek SX et al (2013) PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatr Blood Cancer 60(9):1411–1417 CrossRef Skapek SX et al (2013) PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatr Blood Cancer 60(9):1411–1417 CrossRef
13.
Zurück zum Zitat Bisogno G et al (2021) Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas. Pediatr Blood Cancer 68(7):e28951 CrossRef Bisogno G et al (2021) Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas. Pediatr Blood Cancer 68(7):e28951 CrossRef
14.
Zurück zum Zitat Bisogno G et al (2020) A new standard of care for patients with high-risk rhabdomyosarcoma?—Authors’ reply. Lancet Oncol 21(1):e3 CrossRef Bisogno G et al (2020) A new standard of care for patients with high-risk rhabdomyosarcoma?—Authors’ reply. Lancet Oncol 21(1):e3 CrossRef
15.
Zurück zum Zitat Bisogno G et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20(11):1566–1575 CrossRef Bisogno G et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20(11):1566–1575 CrossRef
16.
Zurück zum Zitat Shern JF et al (2014) Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 4(2):216–231 CrossRef Shern JF et al (2014) Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 4(2):216–231 CrossRef
17.
Zurück zum Zitat Seki M et al (2015) Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun 6:7557 CrossRef Seki M et al (2015) Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun 6:7557 CrossRef
18.
Zurück zum Zitat Chen L et al (2015) Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet 11(3):e1005075 CrossRef Chen L et al (2015) Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet 11(3):e1005075 CrossRef
19.
Zurück zum Zitat Stratton MR et al (1989) Detection of point mutations in N‑ras and K‑ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 49(22):6324–6327 PubMed Stratton MR et al (1989) Detection of point mutations in N‑ras and K‑ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 49(22):6324–6327 PubMed
20.
Zurück zum Zitat Chen X et al (2013) Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24(6):710–724 CrossRef Chen X et al (2013) Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24(6):710–724 CrossRef
21.
Zurück zum Zitat Malempati S et al (2011) Rhabdomyosarcoma in infants younger than 1 year: a report from the Children’s Oncology Group. Cancer 117(15):3493–3501 CrossRef Malempati S et al (2011) Rhabdomyosarcoma in infants younger than 1 year: a report from the Children’s Oncology Group. Cancer 117(15):3493–3501 CrossRef
22.
Zurück zum Zitat Joshi D et al (2004) Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer 42(1):64–73 CrossRef Joshi D et al (2004) Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer 42(1):64–73 CrossRef
23.
Zurück zum Zitat Sparber-Sauer M et al (2019) Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer 66(6):e27652 CrossRef Sparber-Sauer M et al (2019) Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer 66(6):e27652 CrossRef
24.
Zurück zum Zitat Li FP, Fraumeni JF Jr. (1969) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43(6):1365–1373 PubMed Li FP, Fraumeni JF Jr. (1969) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43(6):1365–1373 PubMed
25.
Zurück zum Zitat Kohsaka S et al (2014) A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 46(6):595–600 CrossRef Kohsaka S et al (2014) A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 46(6):595–600 CrossRef
26.
Zurück zum Zitat Casey DL et al (2020) Genomic determinants of clinical outcomes in rhabdomyosarcoma. Clin Cancer Res 26(5):1135–1140 CrossRef Casey DL et al (2020) Genomic determinants of clinical outcomes in rhabdomyosarcoma. Clin Cancer Res 26(5):1135–1140 CrossRef
Metadaten
Titel
Genomische Klassifizierung und Überleben von Patienten mit Rhabdomyosarkom: Bericht eines internationalen Konsortiums
verfasst von
PD Dr. med. Monika Sparber-Sauer
Publikationsdatum
01.03.2022
Verlag
Springer Berlin Heidelberg
Schlagwort
Rhabdomyosarkome
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 4/2022
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-022-01908-3

Weitere Artikel der Ausgabe 4/2022

Strahlentherapie und Onkologie 4/2022 Zur Ausgabe

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.